Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-21
2011-06-21
Wang, Shengjun (Department: 1627)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S063000, C548S110000
Reexamination Certificate
active
07964738
ABSTRACT:
Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardiovascular disorders and cancer are described. The compositions and methods are effective at decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of non-selective carboxylate-containing-nonsteroidal anti-inflammatory drugs.
REFERENCES:
patent: 3285908 (1966-11-01), Shen
patent: 3336194 (1967-08-01), Shen
patent: 5436265 (1995-07-01), Black et al.
patent: 5510368 (1996-04-01), Lau et al.
patent: 5607966 (1997-03-01), Hellberg et al.
patent: 5681964 (1997-10-01), Ashton et al.
patent: 5811438 (1998-09-01), Hellberg et al.
patent: 6399647 (2002-06-01), Kalgutkar et al.
patent: 2002/0160988 (2002-10-01), Amitai et al.
patent: WO 96/01830 (1996-01-01), None
International Search Report and written opinion from corresponding PCT Application No. PCT/US2005/013233 dated Dec. 15, 2006.
J. Schwartz, Remingtons's Pharmaceutical Sciences, Part 8 “Pharmaceutical Preparations and Their Manufacture”, pp. 1435-1694, 1990.
W. Black, et al. “From Indomethacin to a Selective COX-2 Inhibitor: Development of Indolalkanoic Acids as Potent and Selective Cyclooxygenase-2 Inhibitors” Bioorganic & Medical Chemistry Letters, vol. 6, No. 6, pp. 725-730 (1996).
Chan, et al. “Pharmacology of a Selective Cyclooxygenase-2 Inhibitor, L-745,337: A Novel Nonsteroidal Anti-inflammatory Agent with an Ulcerogenic Sparing.Effect in Rat and Nonhuman Primate Stomach” The Journal of Pharmacology and Experimental Therapeutics, vol. 274, No. 3, pp. 1531-1537 (1995).
Flynn, et al. “Nonsteroidal Antiinflammatory Drug Hydroxamic Acids. Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase” J. Med. Chem, vol. 33, No. 8, pp. 2070-2072 (1990).
Futaki, et al. “NS-398, a New Anti-inflammatory Agent, Selectively Inhibits Prostaglandin G/H Synthase/Cyclooxygenase (COX-2) Activity in Vitro” Prostaglandins, vol. 47, pp. 55-59 (1994).
Gans, et al. “Anti-Inflammatory and Safety Profile of DuP 697, a Novel Orally Effective Prostaglandin Synthesis Inhibitor” J Pharmacol Exp. Ther., vol. 254, pp. 180-187 (1990).
Kalgutkar, et al. “Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2” Science, vol. 280, pp. 1268-1270 (May 22, 1998).
Khanna, et al. “1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents” J. Med. Chem., vol. 40, No. 11, pp. 1634-1647 (1997).
Khanna, et al. “1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2” J. Med. Chem., vol. 40, No. 11, pp. 1619-1633 (1997).
Kolasa, et al. “Nonsteroidal Anti-Inflammatory Drugs as Scaffolds for the Design of 5-Lipoxygenase Inhibitors” J. Med. Chem., vol. 40, No. 5, pp. 819-824 (1997).
Li, et al. “Cyclooxygenase-2 Inhibitors. Synthesis and Pharmacological Activities of 5-Methanesulfonamido-1-indanone Derivatives” J. Med. Chem., vol. 38, No. 25, pp. 4897-4905 (1995).
Li, et al. “1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-inflammatory Agents” J. Med. Chem., vol. 38, No. 22, pp. 4570-4578 (1995).
Li, et al. “Novel Terphenyls as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-inflammatory Agents” J. Med. Chem., vol. 39, No. 9, pp. 1846-1856 (1996).
Luong, et al. “Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2” Nature Structural Biology, vol. 3, No. 11, pp. 927-933 (1996).
Meade, et al. “Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Anti-inflammatory Drugs” The Journal of Biological Chemistry, vol. 268, No. 9 pp. 6610-6614 (1993).
Nakamura, et al. “Studies of Antiinflammatory Agents. II. Synthesis and Pharmacological Properties of 2′-(Phenylthio)methanesulfonanilides and Related Derivatives” Chem. Pharm. Bull., vol. 41, No. 5, pp. 894-906 (1993).
Tsuji, et al. “Studies of Anti-inflammatory Agents. IV. Synthesis and Pharmacological Properties of 1, 5-Diarylpyrazoles and Related Derivatives” Chem. Pharm. Bull., vol. 45, No. 6, pp. 987-995 (1997).
Penning, et al. Synthesis and Biological Evaluation of the 1, 5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib) J. Med. Chem., vol. 40, No. 9, pp. 1347-1365 (1997).
Prasit, et al. “L-745,337: A Selective Cyclooxygenase-2 Inhibitior” Medicinal Chemistry Research, vol. 5, pp. 364-374 (1995).
Reitz, et al. “Novel 1, 2-Diarylcyclopentenes are Selective, Potent, and Orally Active Cyclooxygenase Inhibitors” Medicinal Chemistry Research, vol. 5, pp. 351-363 (1995).
Remmel, et al. “Studies on the Metabolism of the Novel, Selective Cyclooxygenase-2 Inhibitor Indomethacin Phenethylamide in Rat, Mouse, and Human Liver Microsomes: Identification of Active Metabolites” Drug Metabolism and Disposition, vol. 32, No. 1, pp. 113-122 (2004).
Riendeau, et al. “Biochemical and Pharmacological Profile of a Tetrasubstituted furanone as a Highly Selective COX-2 Inhibitor” British Journal of Pharmacology, vol. 121, pp. 105-117 (1997).
Leblanc, et al. “A New Series of Selective COX-2 Inhibitors: 5, 6-Diarylthiazolo [3,2-b][1,2,4]Triazoles” Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 1., pp. 57-62 (1997).
Showell, et al. “Chemistry Challenges in Lead Optimization: Silicon Isosteres in Drug Discovery” Drug Discovery Today, vol. 8, No. 12, pp. 551-556 (2003).
Tacke, et al. “Sila-substitution—A Usefult Strategy for Drug Design” Endeavour, vol. 10, No. 4, pp. 191-197 (1986).
Tanaka, et al. “Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one” Arzneimittelforschung, vol. 42, No. 7, pp. 935-944, 1992.
Therien, et al. “Synthesis and Biological Evaluation of 5, 6-Diarylimidazo [2.1-b]Thiazole as Selective COX-2 Inhibitors” Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 1, pp. 47-52 (1997).
Vane, et al. “Inducible Isoforms of Cyclooxygenase and Nitric-Oxide Synthase in Inflammation” Proc. Natl. Acad. Sci. USA, vol. 91, pp. 2046-2050 (1994).
Wiesenberg, et al. “The Pharmacological Profile of CGP 28238, A Novel Highly Potent Anti-Inflammatory Compound” Drugs Exptl. Clin. Res., vol. 15, pp. 501-509 (1989).
Futaki, et al. “NS-398, A Novel Non-Steroidal Anti-Inflammatory Drug with Potent Analgesic and Antipyretic Effects, Which Causes Minimal Stomach Lesions” Gen. Pharmac., vol. 24, No. 1, pp. 105-110 (1993).
Klein, et al. “Selective Inhibition of Cyclooxygenase 2” Biochemical Pharacology, vol. 48, No. 8, pp. 1605-1610 (1994).
Gately Stephen
Wanaski Stephen P.
Duane Morris LLP
Gould Robert M.
Silamed, Inc.
Wang Shengjun
LandOfFree
Pharmaceutical compositions and methods of use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods of use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods of use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729301